RxDoctor Payments Data

Devan Miller, PA

Physician Assistant · Citrus Heights, CANPI 1225412869

Payments from drug & device makers

$2,083in general payments, 2019–2025

Across 21 payments — averaging $99.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$682
  • AbbVie$554
  • Galderma Laboratories, L.p.$268
  • Inspire Medical Systems, Inc.$153
  • Si-bone, Inc.$112
  • Sanofi-aventis U.S. LLC$96
  • plus $218 from 3 others

What the payments were for

  • Food & beverage$2,083100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,083 in reported general payments places this provider in the 80th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$74,197
Medicare patients
433
Services billed
851

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban39$37,981
OzempicSemaglutide18$31,558
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$17,622
JanumetSitagliptin Phos/Metformin Hcl14$10,277
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$9,807
FarxigaDapagliflozin Propanediol11$8,520
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$4,025
SynthroidLevothyroxine Sodium20$2,336
Levothyroxine Sodium123$1,481
Atorvastatin Calcium107$1,294
Albuterol Sulfate HfaAlbuterol Sulfate42$1,167
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen51$1,014
Famotidine36$1,009
Rosuvastatin Calcium44$942
Fluticasone Propionate46$815

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBreztri Aerosphere, Farxiga$682$18,32725 claims
AbbVieSynthroid$554$2,33620 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Citrus Heights

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →